壽康集團(00575.HK)授出治療早泄藥物在以色列及巴爾幹地區獨家分銷權
壽康集團(00575.HK)公佈,旗下附屬Solutions昨日(14日)SK-Pharma訂立獨家許可協議,內容有關通過在以色列及巴爾幹地區銷售及分銷Fortacin,將Solutions治療早泄之最新藥品Fortacin商業化之權利。
Solutions 繼續保留在世界餘下地區(包括但不限於美國和加拿大、拉丁美洲、中東及撒哈拉以南非洲地區)將Fortacin完全商業化之權利。
另外在中國,公司已接獲江蘇萬邦醫藥通知,醫療物料現已付運,預期臨牀試驗將自2022年1月開始,期望開始臨牀試驗可作爲Senstend在中國進行商業化之下一關鍵步驟。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.